person · Reporting owner
Klinger Shannon Thyme
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Moderna, Inc.MRNA · Entity 2025 | Chief Legal Officer | September 04, 2026 | September 08, 2026 |
| Rafael Holdings, Inc.RFL · Entity 6620 | Director | January 05, 2022 | January 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Moderna, Inc.
Report date September 04, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 81,340 |
Ending reported balance
After 2026-09-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-04 · Exercise / conversion · Acquired 11,797 · Balance 87,044 F1: Restricted stock units convert into common stock on a one-for-one basis. Row 2 · 2026-09-04 · Tax withholding · Disposed 5,704 · Balance 81,340 F2: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 106,179 |
Reported balance
After 2026-09-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-04 · Exercise / conversion · Disposed 11,797 · Balance 106,179 F1: Restricted stock units convert into common stock on a one-for-one basis. F3: 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
F3: 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter.
Rafael Holdings, Inc.
Report date January 05, 2022 · Filed January 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common Stock, par value $.01 per shareSEC Table I · non-derivative | Direct | 5,412 |
Reported balance
After 2022-01-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-01-05 · Grant · Acquired 5,412 · Balance 5,412 F1: Grant of Restricted Stock that vests in full immediately. F2: Represents the average closing price of the Issuer's Class B common stock during December 2021. F3: Consists of fully vested shares of Restricted Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of Restricted Stock that vests in full immediately.
F2: Represents the average closing price of the Issuer's Class B common stock during December 2021.
F3: Consists of fully vested shares of Restricted Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2024 Filed Mar 1, 2024 22:29 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,315 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-007941 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,227 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:37 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 10,609 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-007634 · form4.xml · derivative · entry 5 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,609 Underlying: Common Stock · 10,609 shares Expires not disclosed F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award will vest on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award will vest on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:37 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 60,216 | $0.00 Strike: $96.20 | $0.00 |
DisclosureSEC source: 0001127602-24-007634 · form4.xml · derivative · entry 4 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,216 Underlying: Common Stock · 60,216 shares Expires 2034-02-27 F3 · derivative.exercise_date: 50% of this option will vest and become exercisable on February 27, 2026 and the remaining 50% will vest and become exercisable on February 27, 2027, subject to the recipient's continued service. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:37 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 12,377 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-007634 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,377 Underlying: Common Stock · 12,377 shares Expires not disclosed F2 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award will vest on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F2 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award will vest on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:37 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 23,635 | $0.00 Strike: $96.20 | $0.00 |
DisclosureSEC source: 0001127602-24-007634 · form4.xml · derivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,635 Underlying: Common Stock · 23,635 shares Expires 2034-02-27 F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| December 08, 2023 Filed Dec 11, 2023 21:03 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 563 | $79.09 | $44,525.08 |
DisclosureSEC source: 0001127602-23-029191 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,912 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 21:03 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-029191 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,832 Underlying: Common Stock · 1,139 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 21:03 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,139 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-029191 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 04, 2023 Filed Dec 5, 2023 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 111 | $79.31 | $8,803.79 |
DisclosureSEC source: 0001127602-23-028862 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,336 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 232 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-028862 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,094 Underlying: Common Stock · 232 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 232 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-028862 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| September 08, 2023 Filed Sep 11, 2023 20:02 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 557 | $107.22 | $59,722.10 |
DisclosureSEC source: 0001127602-23-023964 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,215 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| September 07, 2023 Filed Sep 11, 2023 20:02 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-023964 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,971 Underlying: Common Stock · 1,138 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| September 07, 2023 Filed Sep 11, 2023 20:02 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,138 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-023964 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,772 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 20:17 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 115 | $111.44 | $12,815.14 |
DisclosureSEC source: 0001127602-23-023779 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,634 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 20:17 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 233 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-023779 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,326 Underlying: Common Stock · 233 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 20:17 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 233 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-023779 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 20:09 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 565 | $124.09 | $70,110.79 |
DisclosureSEC source: 0001127602-23-018413 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,516 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:09 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-018413 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,109 Underlying: Common Stock · 1,139 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:09 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,139 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-018413 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 02, 2023 Filed Jun 5, 2023 20:20 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 110 | $130.32 | $14,335.55 |
DisclosureSEC source: 0001127602-23-017845 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,942 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:20 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 232 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-017845 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,559 Underlying: Common Stock · 232 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:20 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 232 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-017845 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 21:13 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 561 | $141.51 | $79,387.61 |
DisclosureSEC source: 0001127602-23-009563 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,820 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:13 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,138 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-009563 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,248 Underlying: Common Stock · 1,138 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:13 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-009563 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:21 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 459 | $136.43 | $62,623.16 |
DisclosureSEC source: 0001127602-23-008700 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,243 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:21 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 930 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-008700 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,791 Underlying: Common Stock · 930 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:21 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 930 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-008700 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 23:09 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 5,260 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-008467 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,260 Underlying: Common Stock · 5,260 shares Expires not disclosed F2 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award will vest on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F2 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award will vest on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 23:09 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 20,040 | $0.00 Strike: $138.81 | $0.00 |
DisclosureSEC source: 0001127602-23-008467 · form4.xml · derivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,040 Underlying: Common Stock · 20,040 shares Expires 2033-02-28 F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 21:07 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 490 | $179.15 | $87,783.30 |
DisclosureSEC source: 0001127602-22-027176 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,772 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 21:07 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,139 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-027176 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,386 Underlying: Common Stock · 1,139 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 21:07 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-027176 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · balance_after: Includes 174 shares acquired under the Moderna, Inc. 2018 Employee Stock Purchase Plan on November 30, 2022. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 20:17 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 478 | $137.44 | $65,698.42 |
DisclosureSEC source: 0001127602-22-022253 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,949 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 20:17 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,138 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-022253 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,525 Underlying: Common Stock · 1,138 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 20:17 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-022253 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 20:14 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,265 | $148.12 | $187,370.66 |
DisclosureSEC source: 0001127602-22-017115 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,289 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 4,554 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-017115 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,663 Underlying: Common Stock · 4,554 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 4,554 | $140.00 | $637,560.00 |
DisclosureSEC source: 0001127602-22-017115 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:51 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 3,721 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-008024 · form4.xml · derivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,721 Underlying: Common Stock · 3,721 shares Expires not disclosed F2 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award will vest on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F2 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award will vest on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:51 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 15,091 | $0.00 Strike: $149.52 | $0.00 |
DisclosureSEC source: 0001127602-22-008024 · form4.xml · derivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,091 Underlying: Common Stock · 15,091 shares Expires 2032-03-01 F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| January 05, 2022 Filed Jan 5, 2022 17:32 UTC | Rafael Holdings, Inc. RFL · Entity 6620 | GrantClass B Common Stock, par value $.01 per share | 5,412 | $5.39 | $29,170.68 |
DisclosureSEC source: 0001209191-22-001448 · doc4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,412 F1 · shares: Grant of Restricted Stock that vests in full immediately. F2 · price: Represents the average closing price of the Issuer's Class B common stock during December 2021. F3 · balance_after: Consists of fully vested shares of Restricted Stock. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:10 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 9,108 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-019513 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,108 Underlying: Common Stock · 9,108 shares Expires not disclosed F3 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on June 7, 2024, subject to the recipient's continued service. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:10 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 18,217 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-019513 · form4.xml · derivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,217 Underlying: Common Stock · 18,217 shares Expires not disclosed F2 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award will vest on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:10 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 42,169 | $0.00 Strike: $219.57 | $0.00 |
DisclosureSEC source: 0001127602-21-019513 · form4.xml · derivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,169 Underlying: Common Stock · 42,169 shares Expires 2031-06-07 F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.